Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ

Watchlist Manager
Eckert & Ziegler Strahlen und Medizintechnik AG Logo
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
Watchlist
Price: 39.88 EUR 7.84% Market Closed
Market Cap: 831.3m EUR
Have any thoughts about
Eckert & Ziegler Strahlen und Medizintechnik AG?
Write Note

Eckert & Ziegler Strahlen und Medizintechnik AG
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Eckert & Ziegler Strahlen und Medizintechnik AG
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
Cost of Revenue
-€216.7m
CAGR 3-Years
-37%
CAGR 5-Years
-19%
CAGR 10-Years
-13%
Carl Zeiss Meditec AG
XETRA:AFX
Cost of Revenue
-€927.4m
CAGR 3-Years
-6%
CAGR 5-Years
-5%
CAGR 10-Years
-8%
Stratec SE
XETRA:SBS
Cost of Revenue
-€182.8m
CAGR 3-Years
4%
CAGR 5-Years
-3%
CAGR 10-Years
-7%
Siemens Healthineers AG
XETRA:SHL
Cost of Revenue
-€13.7B
CAGR 3-Years
-10%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Draegerwerk AG & Co KGaA
XETRA:DRW8
Cost of Revenue
-€1.9B
CAGR 3-Years
-1%
CAGR 5-Years
-4%
CAGR 10-Years
-4%
Sartorius AG
XETRA:SRT
Cost of Revenue
-€1.9B
CAGR 3-Years
-8%
CAGR 5-Years
-17%
CAGR 10-Years
-16%
No Stocks Found

Eckert & Ziegler Strahlen und Medizintechnik AG
Glance View

Market Cap
831.3m EUR
Industry
Health Care

Eckert & Ziegler Strahlen- und Medizintechnik AG engages in the provision of isotope technology for medical, scientific, and industrial use. The company is headquartered in Berlin, Berlin and currently employs 866 full-time employees. The company went IPO on 2008-02-25. The firm operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.

EUZ Intrinsic Value
56.66 EUR
Undervaluation 30%
Intrinsic Value
Price

See Also

What is Eckert & Ziegler Strahlen und Medizintechnik AG's Cost of Revenue?
Cost of Revenue
-216.7m EUR

Based on the financial report for Sep 30, 2024, Eckert & Ziegler Strahlen und Medizintechnik AG's Cost of Revenue amounts to -216.7m EUR.

What is Eckert & Ziegler Strahlen und Medizintechnik AG's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-13%

Over the last year, the Cost of Revenue growth was -67%. The average annual Cost of Revenue growth rates for Eckert & Ziegler Strahlen und Medizintechnik AG have been -37% over the past three years , -19% over the past five years , and -13% over the past ten years .

Back to Top